Introduction. The objective was to assess the impact of robot-assisted radical hysterectomy (RRH) on surgical and oncologic outcome and costs compared with open radical hysterectomy (ORH) at a tertiary referral center in Sweden. Material and methods. In this retrospective analysis all patients treated with radical hysterectomy and pelvic lymphadenectomy for early stage uterine cervical cancer during 2006-2015 were included (n = 304). The patients were divided into two groups, ORH (n = 155) and RRH (n = 149). Patient characteristics, FIGO stage, histology, adjuvant therapy, operation time, length of stay (LOS), lymph node yield, recurrence rate and survival were retrieved from medical records. Complications were graded according to the ClavienDindo classification. In addition, costs related to the surgical treatments were calculated. Results. Blood loss, LOS and intraoperative complications were significantly lower as well as lymph node yield after RRH. No differences in postoperative complications or costs were observed between the two groups. Recurrence of disease was detected in 13.4 and 10.3% after RRH and ORH, respectively. Regression analysis demonstrated that histology, tumor size, positive lymph nodes and type of operation (RRH) were significantly associated with recurrence. Conclusion. The introduction of RRH was accompanied by similar postoperative complication rates and costs but lower LOS compared with ORH. An initial learning curve may account for the higher recurrence rate observed after RRH. These data reinforce the need for structured training and monitoring of outcomes when novel treatment modalities are introduced.
Introduction
Radical hysterectomy with pelvic lymphadenectomy constitutes the cornerstone of surgical treatment of early stage cervical cancer. In recent years, minimally invasive surgery (MIS) has emerged as an alternative to traditional
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Robot-assisted radical hysterectomy for early stage cervical cancer was accompanied by similar postoperative complication rates (37.6% vs. 37.4%) and costs but shorter hospital stay compared with open radical hysterectomy. open surgery. MIS is associated with less postoperative pain and shorter hospital stay (1) compared with open radical hysterectomy (ORH). Despite these advantages, laparoscopic radical hysterectomy has not been widely adopted due to a relatively long learning curve and ergonomic disadvantages (2, 3) . Robot-assisted laparoscopy for radical hysterectomy (RRH) offers improved visibility, precision and ergonomics for the surgeon compared with traditional laparoscopy. Theoretically, a more precise dissection can be achieved with potentially better patientrelated outcomes.
Several studies suggest that RRH for cervical cancer has advantages over the traditional open technique in terms of shorter hospital stay, fewer complications and reduced blood loss (4) (5) (6) (7) . In high volume settings (>400 robotassisted operations annually), equal hospital costs can be achieved in spite of higher costs related to acquisition and maintenance of the robotic system (8) . In addition, a limited number of studies suggest that the oncologic outcome (recurrence rate) is comparable between RRH and ORH (9) (10) (11) (12) (13) .
RRH was introduced at Karolinska University Hospital (KUH), a tertiary referral center, in 2009 and has gradually replaced the traditional open technique. To assess the impact on perioperative and oncologic outcomes and costs we performed a retrospective analysis comparing ORH with RRH in 2006-2015.
Material and methods
All women with FIGO stage IA1-IB1 and IIA1, treated with type B or C radical hysterectomy (14) during 2006-2015, at KUH were identified. Radical hysterectomy was performed in stage IA1 in the case of positive lymphovascular space invasion (LVSI). After exclusion of five women with rare histology types (one melanoma, one gastric cancer and three sarcomas), a total of 304 cases were included in the study. The women were divided into two groups: ORH performed during the entire study period (n = 155) and RRH performed from August 2009 to December 2015 (n = 149). The surgical procedures (ORH and RRH) have been described previously (4, 15) . The RRHs were performed by three surgeons, competent in both surgical modalities and with individual experience from >25 robot-assisted procedures before the onset of this study.
Age, body mass index, physical status classification (ASA, American Society of Anesthesiologists), FIGO staging, histology, tumor size, operative time (OT), estimated blood loss, lymph node yield, length of stay (LOS), follow-up time, transfusions, readmission within 30 days, conversions and complications were retrieved from the medical records.
To assess the oncologic safety we registered lymph node metastases, surgical margins, LVSI, cervical stroma infiltration, use of preoperative treatment, adjuvant treatment, recurrence rate and mortality. We also calculated the progression-free survival, overall survival and diseasespecific survival.
OT was defined as the time from skin incision to skin closure. LOS was defined as the time from the operation day to the day of discharge from the hospital. Tumor size was defined as the preoperative diameter assessed either in cone specimens or at examination under anesthesia. The time to recurrence was calculated from the date of surgery until the patient had the recurrence confirmed by histopathology and/or radiology. The overall survival was defined as time from date of surgery to death. The disease-specific survival was defined as time from surgery to cervical cancer-related death. We followed the patients until 31 May 2016 or death.
The Clavien-Dindo (CD) classification (16, 17) was used to grade the complications. The complications were divided in early (≤30 days after surgery) and late complications (>30 days).
Adjuvant therapy consists of a combination of radiochemotherapy with external beam radiotherapy delivered by a four-field technique of 45 Gy together with two to three brachytherapy insertions (5 Gy per fraction) and weekly cisplatin 40 mg/m 2 . Indication for adjuvant treatment includes lymph node metastases, positive or close (<5 mm) surgical margins or two or more of the following criteria: LVSI, deep stromal invasion, tumor diameter >4 cm. Preoperative intracavitary brachytherapy (ICBT, 12 Gy 9 2), was administrated for a large proportion of tumors >2 cm before 2010.
In Sweden, 70% of the regions use a case-costing system where all patient-related costs are registered individually. This includes all associated costs of ward care (staff, radiology, laboratory, medication) as well as costs related to activities performed in the operation theater, postoperative care and pharmaceuticals. To calculate the additional costs specific for robotic surgery we used the calculations of Reynisson and Persson, which are based on a seven-year depreciation for the robot and an annual case load of 350 procedures/system (8) . For comparative purposes, we converted Swedish kronor (SEK) to US dollars using the 2013 currency rate (US$1 = 6.51 SEK). Costs related to complications within 30 days after surgery were included in the analyses. All costs were adjusted for inflation in 2006-2015.
Statistical analyses
Statistical analysis was performed using the IBM SPSS for Windows version 23.0 (IBM Corp., Armonk, NY, USA). A t-test was used in the case of continuous variables and Fisher's exact test for discrete variables. Analysis of risk factors for recurrence was done with Cox regression. Statistical significance was defined as p < 0.05. The study was approved by the regional ethics committee at Karolinska Institute, Stockholm, Sweden (no. 2015/2140-32, date of approval 1 January 2016). Figure 1 shows the gradual implementation of RRH at KUH between 2009 and 2015. Patient, tumor characteristics and surgical outcomes are summarized in Table 1 and the oncologic outcomes in Table 2 . No significant differences were found regarding age, body mass index ASA or preoperative tumor size between the two groups. The predominant histology was squamous cell carcinoma (60.6%) followed by adenocarcinoma (31.3%), and the majority of the women were staged as FIGO IB1 (84.5%). LVSI were more common (32.5% vs. 20.6%, p < 0.05) in the RRH group. RRH was associated with shorter LOS (6.3 days vs. 2.4 days, p < 0.0001) and a much higher readmission rate within 30 days (12.1% vs. 1.3%, p = 0.0001). Number of lymph nodes retrieved was lower in the RRH group than in the ORH group (22.7 vs. 28.9, p < 0.0001). Preoperative ICBT was less frequent before RRH than before ORH (2.0% vs. 30.3%, p < 0.0001) One conversion from RRH to ORH due to malfunction of a robotic arm was recorded.
Results
In all, 9.7% in the ORH suffered from intraoperative complications, mainly hemorrhage, compared with 2.7% in the RRH group (p < 0.05; Table 3 ). There were no differences in severe complications defined as ClavienDindo grade ≥III between the groups, and no grade IV-V complications were recorded in either group. In the ORH group, the four early CD III complications consisted of two ureter injuries, one intra-abdominal abscess and one abdominal wall hematoma. Late complications occurred in seven patients after ORH: one lymphocele and one abdominal abscess (IIIa), and two injuries of the ureter, one hernia of the abdominal wall, one vaginal cuff dehiscence and one reoperation due to pain and abdominal adhesions after 18 months (IIIb).
In the RRH group, the early CD III complications consisted of one pelvic abscess (IIIa), one port site hernia (IIIb) and one ureter injury (IIIb). Nine patients suffered late complications after RRH: one injury to the ureter and one lymphocele (IIIa), one vesicovaginal fistula, one ureterolitectomia and five vaginal cuff dehiscences (IIIb).
Overall costs were comparable (17 913 USD vs. 18 719 USD) for ORH and RRH, respectively (Table 4) . No learning-curve effects in terms of decrease in cost were seen when RRH was divided into consecutive groups of 30 operations.
Total recurrence rate was 13.4% after RRH and 10.3% after ORH. Loco-regional recurrences were observed in 8.1 and 3.9% after RRH and ORH, respectively. The use of adjuvant treatment was lower after RRH (29.7% vs. 20.1%, p = 0.06) than after ORH.
The five-year progression-free survival was 82.5 and 90.7% for RRH and ORH, respectively, the five-year disease-free survival was 91.1 and 95.2%, and the five-year overall survival was 91.1% vs. 92.7%. Using Cox regression analysis, we calculated hazard ratios for recurrence of disease in both uni-and multivariable analyses (Table 5 ). Adenocarcinoma and other histology types, tumor size >4 cm, positive lymph nodes and type of operation (RRH) were all associated with recurrence of disease. In univariate analysis, adjuvant therapy and LVSI did not have any impact on recurrence.
To assess the potential impact of preoperative ICBT on recurrence, a separate Cox analysis was performed for the ORH group. Adjusted for tumor size, no association was observed for ICBT with recurrence of disease (hazard ratio 1.70, 95% CI 0.51-5.68).
Discussion
This study is one of the largest single-center studies of perioperative and oncologic outcomes comparing RRH and ORH. We found no significant differences between women treated with RRH or ORH in terms of postoperative complications or costs. In addition, the study confirms previous reports demonstrating that RRH is accompanied by fewer intraoperative complications, shorter LOS and less need for blood transfusions.
However, recurrence of disease was higher among women treated with RRH, possibly associated with an initial learning curve.
As expected, perioperative outcomes traditionally associated with MIS (shorter LOS, less estimated blood loss) were significantly better after RRH. From a patient's perspective, these easily measurable parameters may be regarded as pseudo markers for better outcomes, since it is uncertain whether they translate into better quality of life or survival. However, shorter LOS has a direct impact on institutional costs and largely explains the surprisingly low overall costs observed in the RRH group. Most studies show that robot-assisted surgery is a major cost driver, although lower costs can be achieved after an initial learning curve (18) . Persson and Reynisson recently demonstrated that costs related to RRH dropped as a function of reduced OT and shorter LOS and reached similar costs compared with ORH after 90 operations (8).
As we did not see any decline in OT or LOS over time, we speculate that the robotic program benefited from experiences communicated by early adopters. From the very start of the program, a meticulous follow-up system of outcomes and costs was employed. In addition, "system competence" including skills of the anesthesiologists and other staff members, was gained from the urology program that started at KUH in 2001. The lack of decrease in OT, which could be expected with improved team skills, suggests a "hidden" learning curve as a more extensive RH developed over the years. The use of preoperative ICBT before 2010 resulted in a smaller preoperative tumor volume and a less radical approach was adopted. Furthermore, the implementation of RRH coincided with the publication of the new RH classification by Querleu and Morrow (14) , which simplified tailoring of the procedure. Initially, radical hysterectomy type B was mainly performed and with increased experience, a gradual shift to type C1 was implemented. Overall, 43 (28.7%) type C1 RRHs were performed during the last 23 months of the study period. This shift towards a more radical surgery constitutes a potential source of bias and reflects the clinical reality where changes in management are introduced gradually. Whether a more extensive radical hysterectomy translates into better survival is debated (19) . A learning curve could also explain the lower lymph node count observed in the RRH group, although other factors, including the protocol for histopathology of removed lymphatic tissue, must be taken into account. More importantly, the rate of lymph node metastases was similar between the two groups, albeit higher after ORH compared with RRH (14.2% vs. 8.7%). The increasing use of preoperative MRI has altered the management of early stage cervical cancer, since suspected metastatic nodes may be detected prior to surgery. When including women in whom a scheduled RRH was abandoned in favor of laparoscopic node extirpation, a higher rate of positive nodes was observed in both groups (14.7% vs. 12.3%).
In agreement with recent publications, we observed considerably less intraoperative complications after RRH but a similar rate of postoperative adverse events compared with ORH (10, 20) The panorama of complications was comparable between the groups with the exception of vaginal cuff dehiscence (five vs. one after RRH and ORH, respectively). Vaginal cuff dehiscence is a well-known complication after robot-assisted hysterectomy and is probably caused by excessive use of electrocoagulation and/or incorrect suture technique (21) . Furthermore, significantly more women were readmitted within 30 days in RRH group, mainly because of minor complications including urinary tract infections and lymphatic leakage. These complications typically appear within the first week after surgery and were managed during the longer hospital stay after ORH.
A limited number of studies suggest that the oncologic outcome is comparable between RRH and ORH, although randomized trials are lacking (9-13). The crude recurrence rates reported in this study are similar to several recent publications. Hoogendam et al. reported a recurrence rate of 12.5% after 100 procedures with a median of 29.5 months follow up (9) . From Belgium, a slightly higher recurrence rate was reported (16.5%); however, the study included more advanced stages of cervical cancer (13) . In the largest study to date, Sert et al. (10) reported a recurrence rate of less than 10% among women operated with both ORH and RRH. In the recent study by Zanagnolo et al. (20) , disease recurrence was observed in 8.8% of women after RRH (20) ; however, women with tumors <3 cm with common histology types were included. Direct comparison is difficult because of differences in type of procedures, disease stage and supplementary therapy. Considering that both groups were similar in size, an excess of approximately five to six loco-regional recurrences occurred after RRH in our series. Apart from LVSI, we did not detect any significant differences regarding tumor characteristics. In the regression analysis, adenocarcinoma and other histology types, together with tumor size and type of operation (RRH), constituted significant risk factors for recurrence. Preoperative ICBT did not seem to have any impact on disease recurrence and it was abandoned at KUH early in 2010, since no prospective studies have demonstrated any survival benefit (22) . The study design precludes firm conclusions regarding the difference and potential causes of the higher recurrence rate after RRH. However, we speculate that an initial learning curve may contribute to the finding. This is to some degree supported by a higher number of recurrences observed during the first 50 compared with the second 50 cases (11 vs. 6) . In light of the data presented by Sert et al. (2016) , it is interesting to note that a higher recurrence rate was reported by the same author 5 years earlier (10, 23) . Together these data reinforce the need for structured training and monitoring of outcomes when novel treatment modalities are introduced.
The strength of the study is the large sample size and the low number lost to follow up. Selection bias is limited, since KUH is the only center in the region performing radical hysterectomies and all women with cervical cancer are evaluated for surgery at our institution. Being a single-center study, we had full control of acquired data and all data was retrieved and analyzed by a non-surgeon. We acknowledge some limitations including information bias due to the retrospective nature of the study. Furthermore, some women may have been treated for postoperative complications at other hospitals.
Apart from the known advantages of MIS, including fewer intraoperative complications, blood transfusions and shorter hospital stay, RRH and ORH seem comparable as to operation time, postoperative complications and costs. A trend towards more loco-regional recurrences was seen in patients treated with RRH and may result from an initial learning curve. Data from the ongoing randomized multicenter trial is needed to definitely establish the safety of RRH (24) . 
